Viking Therapeutics, Inc. Stock News

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Viking Therapeutics (VKTX) shares fell Monday, handing back early gains, as analysts questioned the path ahead for its developmental weight-loss drugs even after news of upbeat results in clinical trials.

US stocks slumped on Monday as investors eagerly waited for the outcome of the US Presidential election on Tuesday.  At the time of writing, the Dow Jones Industrial Average slid 175 points, or 0.4%, while the S&P 500 index dropped 0.2%.

Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell the news reaction is understandable given high investor excitement ahead...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics (NASDAQ:VKTX) shares jumped then fell after it reported results from a trial of its weightloss tablet.  The San Diego company said its phase-one clinical trial of an oral tablet formulation of its VK2735 tablet dosed daily for 28 days resulted in up to 8.2% mean weight loss for some patients, or 6.8% versus a placebo.

Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 4.3% to trade at $74.13 at last glance, reversing course from earlier gains.